INTRODUCTION
Elevated cardiovascular (CV) risk is a serious complication in people with type 2 diabetes mellitus (T2DM), and it is often linked to increased morbidity and mortality. Indeed, approximately two-thirds of people with T2DM die of heart disease or stroke [1, 2] . People with diabetes often have other risk factors for cardiovascular disease (CVD), including obesity, high blood pressure and high lipid levels. Diabetes was once considered a 'risk equivalent' of CVD (i.e., that it placed people at the same risk of a cardiac event as those who had already experienced one). The measurement of glycated hemoglobin A 1c (HbA 1c ) levels in subjects with diabetes has been shown to help predict the likelihood of CVD occurring. While HbA 1c remains an important indicator, it is the development of risk engines, in recent years, that have helped to provide a more comprehensive and graded risk of CV complications occurring in patients with diabetes based on a summary of the patient's individual risk factors [3] . Such examples include the United Kingdom Prospective Diabetes Study (UKPDS) risk engine, Oxford risk engine, a 5-year risk model developed by the Swedish National Diabetes Register and the American College of Cardiology/American Heart Association guidelines on the assessment of CV risk [4] [5] [6] . In a recent study, the association between common indicators of diabetes (postprandial glycemia, overall hyperglycemia, glucose variability, and HbA 1c level) and CVD risk factors (lipids, highsensitivity C-reactive protein, and blood pressure) was examined in people with type 1 diabetes mellitus (T1DM) and T2DM. Using linear regression models, it was found that HbA 1c showed the strongest associations with CVD risk [7] . Furthermore, in an observational, registry-based study of people with T2DM, those with tightly controlled baseline HbA 1c levels and blood pressure (median 6.5% and 130/80 mmHg, respectively) had considerably decreased risks of CVD, myocardial infarction (MI), coronary heart disease (CHD), and stroke when followed for 6 years compared with individuals who did not have tight control of HbA 1c levels and blood pressure [8] . A second, similar observational study showed progressively increasing risks of CHD, CVD, and total mortality with higher HbA 1c levels [9] .
This trial showed that people with baseline
HbA 1c levels of 6.0-6.9% (mean 6.5%) had a 20% lower relative risk of CHD and a 16% lower risk of CVD than people with HbA 1c levels of 7.0-7.9% (mean 7.5%) [9] .
These observational studies demonstrate that glycemic control is linked to CV risk in people with T2DM and prospective clinical trials have been undertaken that confirm this association. It is therefore important that people with diabetes receive care that provides both good glycemic control and is optimized to deliver the best CV outcomes possible [10] . Owing to their varied mechanisms of action, different diabetes therapies are likely to have different CV effects.
A review by Holden et al. [11] revealed that the prevalence of insulin use in the UK has risen considerably in the diabetes population and that this is primarily due to the increase in patients with T2DM using insulin, in combination with oral agents, to achieve glycemic control. A 7.5-fold increase was reported in the total number of people with T2DM using insulin in 1991 compared to 2010 (37,000 and 277,400 people, respectively) [11] .
Changes in the management of T2DM have also occurred during this time and this has been reflected in patterns of insulin use over this period. In the USA, in 1997, 2.3 million people with diabetes were on an insulin monotherapy regimen compared to 1.1 million people on insulin combination therapy. In 2010, the number of people with diabetes on insulin monotherapy and combination therapy was 2.8 million and 2.9 million, respectively [11] .
Insulin therapy is considered to be the most effective method of controlling blood glucose, but its influence beyond glycemic control is not widely appreciated. Insulin has been shown to have potent anti-inflammatory effects, to influence blood coagulation and to significantly improve measures of endothelial dysfunction. The aims of this review are to examine CV risk in people with relatively early and mild diabetes with substantial CV risk and consider the impact of insulin therapy on this risk, focusing on key studies in patients with diabetes: the UKPDS [12, 13] , the Action to Control Cardiovascular Risk in Diabetes (ACCORD) [14] , the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) [15] , the Veteran Affairs Diabetes Trial (VADT) [16] , and the Outcome Reduction with Initial Glargine Intervention (ORIGIN) [17] .
METHODS
A literature search was conducted using PubMed to identify key publications between 2008 and 2013 that related to human studies of insulin and its possible impact on CV outcomes in people with T2DM. The search focused on clinical trials, meta-analyses, and relevant substudies of the trials included. Emphasis was placed on combinations of the following words as search terms: cardiovascular, CV; myocardial infarction, MI; stroke; insulin; glargine; detemir; NPH; aspart; lispro; glulisine. The search was limited to articles in the English language. The references of meta-analyses and earlier review studies investigating similar subject matter were also examined to find earlier studies of particular importance and relevance to be included in this review. The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
UKPDS
The UKPDS [12] investigated the effect of intensive glycemic control with either sulfonylurea or insulin compared with conventional treatment in people with newly diagnosed T2DM ( Table 1) . The primary endpoints investigated were risk of diabetesrelated endpoints (sudden death, death from hyperglycemia or hypoglycemia, fatal or nonfatal MI, angina, heart failure, stroke, renal failure, amputation (of at least one digit), vitreous hemorrhage, retinopathy requiring photocoagulation, blindness in one eye or cataract extraction), diabetes-related death (death from MI, stroke, peripheral vascular disease, renal disease, hyperglycemia or hypoglycemia, and sudden death), and allcause mortality over a median of 10 years. The risk of single clinical endpoints, including MI, stroke, and peripheral vascular disease, was also investigated [12] .
The use of intensive treatment targeting fasting plasma glucose (FPG) \6 mmol/L resulted in lower HbA 1c levels after 10 years (7.0% vs. 7.9%) compared with conventional treatment (best achievable FPG on diet alone, with drugs only added if there were hyperglycemic symptoms or FPG [15 mmol/L) [12] . There was a trend toward reduced risk for Table 1 Baseline characteristics and primary and mortality outcomes from UKPDS, ACCORD, ADVANCE, and VADT [12, [14] [15] [16] Study UKPDS [12] ACCORD [14] ADVANCE [15] VADT [16] Number of participants The UKPDS transformed the treatment of people with T2DM and led to the use of more intensive glycemic control in everyday clinical practice. As a result of this, three large clinical trials were initiated to determine whether intensive glycemic control had an impact on CV outcomes. These three trials were:
ACCORD [14] , ADVANCE [15] , and VADT [16] (Table 1) .
ACCORD
The ACCORD trial compared the effect of intensive (target HbA 1c \6.0%) and standard therapy (target HbA 1c 7.0-7.9%) in 10,251 people with T2DM and either established CVD or additional CV risk factors [14] . At the start of the trial, both the intensive and conventional treatment groups had poor glycemic control (HbA 1c 8.3 ± 1.1%) and, after 1 year, both groups achieved stable HbA 1c levels (6.4% and 7.5% in the intensive and conventional treatment groups, respectively). The ACCORD trial was terminated early, after 3.5 years' follow-up, owing to an increased risk of death in the intensive therapy arm [14] . . This effect was only observed after about 3 years and the authors suggest that any benefits from intensive glycemic control might take several years to emerge [14] . There was a significant increase in risk for hypoglycemia (P\0.001), as well as increased risk of weight gain of more than 10 kg (P\0.001) with intensive treatment, and it has been suggested that these might both play a role in the increased mortality associated with intensive control.
Post hoc analyses were performed to investigate whether hypoglycemia was associated with this increased mortality. These analyses found that, even though severe hypoglycemia was associated with an increased risk of death in both study arms, the risk of death in people who experienced at least one severe hypoglycemic episode was lower with intensive control compared with standard care [18] . Conversely, a small but statistically significant inverse relationship between the number of symptomatic and unrecognized hypoglycemic episodes and the risk of death was observed with intensive control compared with standard care [19] . This relationship was, however, of uncertain clinical significance, suggesting that hypoglycemia was not the main driver for the increased mortality seen with intensive control [19] . A post hoc analysis found that severe hypoglycemia was associated with an increased risk for a number of adverse outcomes, including major macro-and microvascular events and mortality [20] . The authors of this analysis highlighted that, as there was no relationship between the number of severe hypoglycemic episodes and adverse event occurrence, it was possible that severe hypoglycemia only acted as a marker of vulnerability [20] . This suggests that even though hypoglycemia may be a contributor to adverse outcomes, there are likely other explanations for the inconsistent outcomes of these trials.
VADT
The VADT compared the effects of intensive (targeting a 1.5% decrease in HbA 1c ) and standard care on CV outcomes in 1,791 people with poorly controlled T2DM [21] . There was a decrease in HbA 1c observed at 3 months; by 6 months, this had stabilized, with HbA 1c levels being maintained in both groups for the remainder of the trial. There was a greater decrease in HbA 1c with intensive treatment and a 1.5% difference in HbA 1c levels was maintained from 6 months to the trial end [21] . No significant difference was observed between the intensive and standard care groups in the primary endpoint, which combined macrovascular and microvascular events and death from CV causes, and there was no difference between groups in death from any cause. There was a greater incidence of adverse events in the intensive therapy group compared with the standard care group (24.1% vs. 17.6%, respectively). The most frequent adverse event was hypoglycemia, which occurred significantly more frequently with intensive therapy (P\0.001) [21] .
Meta-analyses of ACCORD, ADVANCE, VADT, and UKPDS
The ACCORD, ADVANCE and VADT studies failed to demonstrate a reduction in CV mortality with more intensive glycemic control [14] [15] [16] 21] . There was a decrease in microvascular events in the ACCORD study, but no effect on macrovascular outcomes, confirming the results of the 10-year UKPDS [12, 14] . No vascular benefit from intensive control was observed in ADVANCE or VADT [15, 21] . Nonetheless, a meta-analysis including [21]. Other meta-analyses investigating the effect of intensive glycemic control on CV outcomes have been performed, including UKPDS, ADVANCE, ACCORD, and VADT, as well as additional studies [22] [23] [24] [25] [26] .
These analyses reach different conclusions depending on the trials included; however, overall, there appears to be evidence that intensive glycemic control provides limited CV benefits.
Subanalyses of ACCORD, ADVANCE, VADT, and UKPDS
Owing to the conflicting results from UKPDS, ACCORD, ADVANCE, and VADT, subgroup analyses have been performed to identify whether any subgroups experienced a benefit, which is masked by the presence of people who do not experience this benefit in the overall Fig. 1 The effects of intensive versus standard glycemic control on a major cardiovascular events (CV death or nonfatal MI or non-fatal stroke) and b MI (fatal or non-fatal) [21] . may have experienced fewer fatal or non-fatal CV events than those receiving standard care (P = 0.04 and 0.03, respectively) [14] . Subgroup analysis of the ADVANCE trial found that the results of intensive control were consistent for all subgroups [15] .
The lack of agreement between UKPDS and the other trials (ACCORD, ADVANCE, and VADT) in terms of a reduction in CV risk, with intensive glycemic control in people with T2DM, is likely due to very different follow-up times between them, with only the UKPDS having a follow-up of more than 10 years compared with the shorter follow-up in the other studies [27] . Nevertheless, these studies 
Prospective Studies
The Translating Research Into Action for Diabetes prospective observational study followed 8,334 people with T2DM over 8 years [41] . In this population, it was observed that the use of insulin monotherapy was associated with 1.24-times greater risk for all-cause mortality compared with OAD monotherapy [42] .
However, combination therapy with OAD plus insulin was not associated with increased risk for overall mortality compared with the use of OADs alone. When CV and non-CV mortality were considered separately, the use of insulin was seen to be a risk factor for CV mortality but not non-CV mortality [42] . This highlights that the use of insulin is correlated with CV outcomes. This study did not investigate the different components of insulin therapy and it is possible that, as long-acting insulin analogs predominantly target FPG and rapid-acting analogs target postprandial glucose (PPG), they will have different CV effects. Another prospective observational study by Mellbin et al. [43] found that while there was no significant difference in mortality between insulin, metformin and sulfonylureas, a higher risk of non-fatal MI or stroke was observed in patients with T2DM receiving insulin. According to the study findings, after a median follow-up interval of 2.1 years, a protective effect was seen with metformin and an indeterminate response was observed with sulfonylureas.
Rapid-acting Insulin Analogs
The The association between postprandial hyperglycemia and CV risk has been investigated in other studies. The Diabetes Intervention Study found that, over 11 years, 1-h post-breakfast blood glucose, but not FPG, was associated with a higher risk of MI and death in 1,139 newly diagnosed people with T2DM aged 30-55 years old [45] . The 14-year follow-up to the San Luigi Gonzago Diabetes Study that investigated 505 people with T2DM found that both HbA 1c and 2-h PPG levels were predictors of both CV events and all-cause mortality [46] . The DECODE study, which included 22,514 people with diabetes, also demonstrated that 2-h PPG was a better predictor of both all-cause and CV mortality compared with FPG [47] .
The studies highlight that PPG plays an important role in CV risk and it has been suggested that this could occur because wide glycemic fluctuations induce oxidative stress that damages the vasculature [48] . However, guidelines recommend that insulin is initiated as a basal insulin analog to provide control of FPG and it is, therefore, important to understand whether it has any CV effects [28] .
Long-acting Insulin Analogs
The ORIGIN study was designed in an attempt to determine whether insulin therapy can influence long-term CV outcomes [17] . ORIGIN was a 6-year, randomized, open-label, controlled, international, interventional study. The trial investigated whether insulin glargine, targeting normal FPG versus standard approaches to glycemia management, could reduce CV morbidity and/or mortality in people with early T2DM or prediabetes at high risk of CV events [17] . The ORIGIN study was the first large trial designed to specifically assess the impact of insulin on CV outcomes. Unlike ACCORD, ADVANCE, and VADT, ORIGIN studied patients with prediabetes or early T2DM; therefore, glucose control was more easily achieved and maintained [10] [11] [12] . The study also compared omega-3 polyunsaturated fatty acids (PUFAs) versus placebo in reducing CV events in the same population. A total of 12,537 people glargine compared with standard of care, with a between-group difference of 0.3% (6.2% and 6.5% with glargine and standard of care, respectively). Of those with diabetes at baseline 60% and 45% of the insulin glargine and standard care groups, respectively, had HbA 1c \6.5% at 5 years [50] . Post hoc analysis found that people receiving insulin glargine were more likely to maintain HbA 1c \6.5% than During the study, participants in the insulin glargine group experienced modest weight gain (median change: ?1.6 vs. -0.5 kg for insulin glargine and standard care, respectively) and more episodes of hypoglycemia (rate of severe hypoglycemia 0.01 vs. 0.0031 per person-year for insulin glargine and standard care, respectively) than the standard care group, both of which have been linked to increased CV outcomes in epidemiological studies. In a post hoc analysis, severe hypoglycemia was found to be associated with a greater risk for co-primary outcome, mortality, CV death, and arrhythmic death [51] . Nonetheless, the relative risk of CV outcomes with hypoglycemia was lower with insulin glargine than with standard care, highlighting that insulin glargine itself does not affect CV outcomes.
There was no overall increase in CV outcomes in this study despite increased hypoglycemia and weight gain with insulin glargine treatment, suggesting either that these adverse effects do not cause these outcomes or that any potential harm was offset by a treatment benefit. This beneficial effect is unlikely to be associated with concomitant treatment, as more metformin was used in the standard of care than the insulin glargine arm, suggesting that any treatment benefit was related to insulin glargine itself.
Owing to its design, the ORIGIN study looked specifically at the CV outcomes of insulin glargine treatment and not at the effect of improved glycemic control, and found no association between insulin glargine and CV outcomes. This suggests that the CV benefits reported in previous small-scale or long-term follow-up studies might be related to the metabolic effects of treatment, rather than the insulin itself. Alternatively, it could be that ORIGIN was not of sufficient duration to show a modulation of CV outcomes that may take more than a decade to manifest. 
DISCUSSION
Diabetes is an independent risk factor for CV events; however, it is often associated with a number of comorbidities including obesity.
These comorbidities can themselves be risk factors for CV events, making it difficult to determine the impact of diabetes treatment on CV risk. However, long-term prospective studies have demonstrated that maintaining glycemic control at the levels recommended by the ADA and EASD (HbA 1c \7%) results in a clinically relevant decrease in CV risk [28] .
The optimization of glycemic control, should, therefore, be emphasized for people with diabetes to reduce the risk of CV outcomes.
However, only 35.6-50.0% of people in the USA reach glycemic targets of HbA 1c \7% as suggested by the ADA and EASD [28, 52] . This is, therefore, increasing the risk of CV events in a large proportion of people with diabetes. This poor control could result from a number of factors, including clinical inertia and poor adherence to treatment or blood glucose monitoring; therefore, it is important that the reason for poor glycemic control is determined, enabling the treatment to be individualized, thus ensuring that it has maximal impact. This could include patient education programs, the use of insulin pen devices rather than vial and syringe, and patient-led titration of insulin. The results of the ORIGIN study demonstrate that insulin glargine has no effect on CV outcomes, and the improved outcomes that result from optimal glycemic control suggest that treatment should be intensified when glycemic control worsens to maintain treatment benefits, including the use of insulin as recommended by the ADA/EASD consensus statement [28] .
The ADA/EASD recommends that people with T2DM receive a multifaceted therapy program comprising various CV risk reduction strategies, such as lipid-and blood-pressurelowering therapies, as appropriate [53, 54] . The STENO-2 study demonstrated that the use of intensive multifactorial treatment had sustained beneficial effects on the incidence of vascular complications, as well as rates of allcause and CV-related mortality [54] . Despite the evidence of the effectiveness of combination therapy, 40-88% of people with diabetes worldwide are undertreated [55] . This is clearly an unmet need in the treatment of T2DM.
Effective glycemic control, targeting normoglycemia, is essential for people with diabetes as it reduces the risk of CV complications and mortality. The importance of optimal glycemic control was underscored by the UKPDS, which transformed the way in which diabetes is treated. Subsequently, a series of large prospective clinical trials were performed (ACCORD, ADVANCE, and VADT) that investigated the impact of intensive glycemic control on CV outcomes. Although the trials produced inconsistent results and a definite benefit of intensive control could not be determined, meta-analyses including these trials suggest that there is a benefit, in particular a reduction in the incidence of non-fatal MI.
Indeed, sub-studies of the ACCORD and ADVANCE trials demonstrated that intensive glycemic control is not beneficial for everybody and highlighted the need for personalized care in T2DM. In addition, it was important to determine which treatments would be beneficial for specific subpopulations of people with diabetes. The ORIGIN trial, the first largescale trial specifically investigating the impact of insulin on CV outcomes, demonstrated that insulin glargine was CV neutral in people with IGT and early diabetes and that the beneficial effects seen were predominantly a result of improved glycemic control. However, the possibility that treatment with insulin glargine has additional CV effects beyond glycemic control has not been ruled out.
While there are studies that have suggested a possible increase in CV risk associated with insulin use in patients with T2DM, it is important to highlight that despite the benefits of early insulin use, insulin therapy is often reserved for patients with advanced and long-standing diabetes that is uncontrolled with OADs. Such a population, as a course of their uncontrolled disease, would be expected to be at increased risk of microvascular disease, making it difficult to determine whether the increased risk is attributed to insulin therapy or the study population itself. In addition, the lack of consistent, and often contradictory, findings regarding the effect of insulin on CV outcomes in both retrospective and prospective studies highlights the need for more rigorous research to be carried out in the form of a RCT.
A key limitation of these studies, acknowledged by the authors themselves, is the short duration of follow-up and it is clear that further research needs to be done in this area with a longer duration of follow-up to truly ascertain the extent of the relationship between insulin treatment and CV outcomes in the long term.
CONCLUSION
Optimal glycemic control in people with T2DM
should be determined on a case-by-case basis dependent on each individual's characteristics.
In 
ACKNOWLEDGMENTS
Article processing charges for this study were funded by Sanofi, Bridgewater, New Jersey, USA. 
